It combines 232 genetic polymorphisms with protein biomarkers (PSA, fPSA, iPSA etc.)and clinical variables (age, DRE, family history etc.)When used alone for screening, S3M performed significantly better than PSA for detection of clinically significant prostate cancer (AUC 0.74 versus 0.56) [43]. This evidence concerns the gene KLK3 and prostate cancer.